Page 41 - Read Online

Page 6 of 7 Hafezi et al. Hepatoma Res 2020;6:23 I http://dx.doi.org/10.20517/2394-5079.2020.02

Copyright
© The Author(s) 2020.

REFERENCES
1. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al.; Global Burden of Disease Liver Cancer Collaboration. The burden
of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global
burden of disease study 2015. JAMA Oncol 2017;3:1683-91.
2. Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol
2018;19:222-32.
3. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and
management. Nat Rev Gastroenterol Hepatol 2019;16:589-604.
4. Tang KW, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E. The landscape of viral expression and host gene fusion and
adaptation in human cancer. Nat Commun 2013;4:2513.
5. Krebs K, Bottinger N, Huang LR, Chmielewski M, Arzberger S, et al. T cells expressing a chimeric antigen receptor that binds
hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 2013;145:456-65.
6. Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and
hepatocellular carcinoma cell lines. J Hepatol 2011;55:103-10.
7. Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, et al. A practical approach to immunotherapy of hepatocellular carcinoma using
T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids 2013;2:e114.
8. Kah J, Koh S, Volz T, Ceccarello E, Allweiss L, et al. Lymphocytes transiently expressing virus-specific T cell receptors reduce
hepatitis B virus infection. J Clin Invest 2017;127:3177-88.
9. Lim HK. Radiofrequency thermal ablation of hepatocellular carcinomas. Korean J Radiol 2000;1:175-84.
10. Zhou B, Shan H, Zhu KS, Jiang ZB, Guan SH, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable
recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Vasc Interv Radiol 2010;21:333-8.
11. Na GH, Hong TH, You YK, Kim DG. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver
transplantation. World J Gastroenterol 2016;22:5790-9.
12. Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, et al. Use of expression profiles of HBV-DNA integrated into genomes of
hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology 2019;156:1862-76.e9.
13. Zhang HM, Shi YX, Sun LY, Zhu ZJ. Hepatocellular carcinoma recurrence in living and deceased donor liver transplantation: a
systematic review and meta-analysis. Chin Med J (Engl) 2019;132:1599-609.
14. Sugawara Y. Living-donor liver transplantation for patients with hepatocellular carcinoma in Japan: current situations and challenge.
Hepatobiliary Pancreat Dis Int 2020;19:1-2.
15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008;359:378-90.
16. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
17. Gassmann D, Weiler S, Mertens JC, Reiner CS, Vrugt B, et al. Liver allograft failure after nivolumab treatment-A case report with
systematic literature research. Transplant Direct 2018;4:e376.
18. Hu B, Yang XB, Sang XT. Liver graft rejection following immune checkpoint inhibitors treatment: a review. Med Oncol 2019;36:94.
19. Bertoletti A, Brunetto M, Maini MK, Bonino F, Qasim W, et al. T cell receptor-therapy in HBV-related hepatocellularcarcinoma.
Oncoimmunology 2015;4:e1008354.
20. Kruse RL, Shum T, Tashiro H, Barzi M, Yi Z, et al. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver
chimeric mice. Cytotherapy 2018;20:697-705.
21. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, et al. Immunotherapy of HCC metastases with autologous T cell receptor
redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.
22. Wang Y, Wu MC, Sham JS, Tai LS, Fang Y, et al. Different expression of hepatitis B surface antigen between hepatocellular carcinoma
and its surrounding liver tissue, studied using a tissue microarray. J Pathol 2002;197:610-6.
23. Wong DKH, Cheng SCY, Mak LLY, To EWP, Lo RCL, et al. Among patients with undetectable hepatitis B surface antigen and
hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. Clin Gastroenterol
Hepatol 2020;18:449-56.
24. Chiu YT, Wong JK, Choi SW, Sze KM, Ho DW, et al. Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic
chimera in hepatocellular carcinoma. J Hepatol 2016;64:1256-64.
25. Furuta M, Tanaka H, Shiraishi Y, Uchida T, Imamura M, et al. Correction: characterization of HBV integration patterns and timing in
liver cancer and HBV-infected livers. Oncotarget 2018;9:31789.
26. Furuta M, Tanaka H, Shiraishi Y, Unida T, Imamura M, et al. Characterization of HBV integration patterns and timing in liver cancer
and HBV-infected livers. Oncotarget 2018;9:25075-88.
27. Fu S, Li N, Zhou PC, Huang Y, Zhou RR, et al. Detection of HBV DNA and antigens in HBsAg-positive patients with primary
hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2017;41:415-23.
28. Hou Y, Guo H, Cao C, Li X, Hu B, et al. Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic
heterogeneity in hepatocellular carcinomas. Cell Res 2016;26:304-19.
29. Correction for Ling et al., extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution.
Proc Natl Acad Sci U S A 2016;113:E663.